ALK (for lung carcinoma) pin

IHC

Methodology: IHC

Clinical Significance:
ALK is a proto-oncogene highly expressed in a variety of tumor cells, and in particular in ~2-5% of non-small cell lung carcinomas owing to the presence of a chromosomal 2 EML4-ALK rearrangement. Cytoplasmic localization of ALK can be used to distinguish cancers containing the ALK translocation, with results between IHC and FISH highly concordant. Published data suggest that ALK rearrangement in NSCLC is a strong predictive marker for response to crizotinib. In our validation studies the cutoff for IHC positivity is ≥ 10%. (References: Kwak EL et al., N Engl J Med 363:1693-703, 2010; von Laffert M et al., J Thorac Oncol 9:1685-92, 2014).)

Organ:

Disease State:

CPT Code(s): 88342 or 88341 (reference only; CPTs may vary)

Turnaround Time: Within 1-2 business days of receipt

Schedule: Monday - Friday

Specimen Requirements:
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR -
• 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm